SCHEMBL5205209

SCHEMBL5205209

CCOC(=O)N1CCN(c2cccc3cc[nH]c23)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.61
ALDH1A1 P00352 3/20 0.61
GAA P10253 3/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
KDM4E B2RXH2 4/20 0.49
POLB P06746 3/20 0.49
KMT2A Q03164 2/20 0.49
MAPK1 P28482 2/20 0.49
MEN1 O00255 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
LMNA P02545 2/20 0.48
BCHE P06276 1/20 0.47
TSHR P16473 3/20 0.47
IDO1 P14902 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 2/20 0.46
HSD17B10 Q99714 2/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205461 0.85 IDO1 (0.48) MAPTALDH1A1LMNABCHEIDO1
SCHEMBL30885785 0.85 IDO1 (0.48) MAPTALDH1A1LMNABCHEIDO1
SCHEMBL20141537 0.81 KEAP1 (0.47) MAPTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL3296720 0.77 GOT1 (0.42) MAPTALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL3436308 0.76 MAPT (0.78) MAPTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL7224481 0.74 GAA (1.00) MAPTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL11093641 0.73 GAA (0.72) MAPTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL15651250 0.73 GAA (0.72) MAPTALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL3252759 0.72 PKM (0.78) MAPTALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL27757386 0.72 KEAP1 (0.38) MAPTALDH1A1GAASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401813-B1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY HOFFMANN LA ROCHE (CH) 2007-02-07 EP disclosed
CN-1257892-C New indole derivatives with 5-HT6 receptor affinity HOFFMANN LA ROCHE (CH) 2006-05-31 CN disclosed
US-20050171118-A1 New indole derivatives with 5-HT6 receptor affinity BEARD COLIN C (US) 2005-08-04 US disclosed
US-20040248902-A1 New indole derivatives with 5-HT6 receptor affinity BEARD COLIN CHARLES (US) 2004-12-09 US disclosed
CN-1527816-A Novel indole derivatives having 5-HT 6 receptor affinity - 2004-09-08 CN disclosed
US-6787535-B2 CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-09-07 US disclosed
EP-1401813-A1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY F. Hoffman-la Roche AG (CH) 2004-03-31 EP disclosed
US-20030073700-A1 New indole derivatives with 5HT6 receptor affinity SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC 2003-04-17 US disclosed
WO-2002098857-A1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248902-A1 New indole derivatives with 5-HT6 receptor affinity HTR6, HTR5A, HTR7 MAPT 3221/4885ALDH1A1 1833/4885GAA 4734/4885
US-20050171118-A1 New indole derivatives with 5-HT6 receptor affinity HTR6, HTR5A, HTR7 MAPT 3322/4885ALDH1A1 2354/4885GAA 4813/4885
US-20030073700-A1 New indole derivatives with 5HT6 receptor affinity HTR6, HTR5A, HTR7 MAPT 3421/4885ALDH1A1 1394/4885GAA 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.